Resistance to Androgen-Pathway Drugs in Prostate Cancer: Reply

摘要

Sendur and colleagues correctly point out that a previous study suggests an association between the duration of response to first-line ADT and subsequent responses to additional endocrine manipulations in men with castration-resistant prostate cancer. We did not" observe a difference in the duration of response to primary ADT between the AR-V7-positive and ARrV7-negative patients. In the 18 AR-V7-posi-tive men, the median duration of response to primary ADT was 17 months (range, 1 to 78); in the 44 AR-V7-negative men, the median duration of response to primary ADT was also 17 months (range, 2 to 120). Therefore, it is unlikely that the detection of AR-V7 could be predicted simply on the basis of a short duration of response to first-line ADT.